Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 263

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease

Open access
Klings, Elizabeth S., Machado, Roberto F., Barst, Robyn J., Morris, Claudia R., Mubarak, Kamal K., Gordeuk, Victor R., Kato, Gregory J., Ataga, Kenneth I., Gibbs, J. Simon, Castro, Oswaldo, Rosenzweig, Erika B., Sood, Namita, Hsu, Lewis, Wilson, Kevin C., Telen, Marilyn J., DeCastro, Laura M., Krishnamurti, Lakshmanan, Steinberg, Martin H., Badesch, David B., Gladwin, Mark T.·2014·American Journal of Respiratory and Critical Care Medicine

Abstract

BACKGROUND: In adults with sickle cell disease (SCD), an increased tricuspid regurgitant velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension (PH) diagnosed by right heart catheterization (RHC) are independent risk factors for mortality. METHODS: A multidisciplinary committee was formed by clinician-investigators experienced in the management of patients with PH and/or SCD. Clinically important questions were posed, related evidence was appraised, and questions were answered with evidence-based recommendations. Target audiences include all clinicians who take care of patients with SCD. RESULTS: Mortality risk stratification guides decision making. An increased risk for mortality is defined as a TRV equal to or greater than 2.5 m/second, an NT-pro-BNP level equal to or greater than 160 pg/ml, or RHC-confirmed PH. For patients identified as having increased mortality risk, we make a strong recommendation for hydroxyurea as first-line therapy and a weak recommendation for chronic transfusions as an alternative therapy. For all patients with SCD with elevated TRV alone or elevated NT-pro-BNP alone, and for patients with SCD with RHC-confirmed PH with elevated pulmonary artery wedge pressure and low pulmonary vascular resistance, we make a strong recommendation against PAH-specific therapy. However, for select patients with SCD with RHC-confirmed PH who have elevated pulmonary vascular resistance and normal pulmonary capillary wedge pressure, we make a weak recommendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong recommendation against phosphodiesterase-5 inhibitor therapy. CONCLUSIONS: Evidence-based recommendations for the management of patients with SCD with increased mortality risk are provided, but will require frequent reassessment and updating.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201401-0065st

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Research works printed but not linked: 3

  1. Claster, 1999, Treatment of pulmonary hypertension in sickle cell disease with transfusion [abstract], Blood, 94, 420A
  2. Lisbona, 1997, Scintigraphic evidence of pulmonary vascular occlusion in sickle cell disease, J Nucl Med, 38, 1151
  3. Kanthapillai, 2004, Sildenafil for pulmonary hypertension, Cochrane Database Syst Rev, CD003562

Cited by

See all 263

Metadata

Authors
Klings, E. S., Machado, R. F., Barst, R. J., Morris, C. R., Mubarak, K. K., Gordeuk, V. R., Kato, G. J., Ataga, K. I., Gibbs, J. S., Castro, O., Rosenzweig, E. B., Sood, N., Hsu, L., Wilson, K. C., Telen, M. J., DeCastro, L. M., Krishnamurti, L., Steinberg, M. H., Badesch, D. B., & Gladwin, M. T.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2014-03-15
Volume
189
Issue
6
Pages
727-740
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2123161963
Cited by
263
References
75
FWCI
13.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. https://app.cochat.ai/papers/10.1164/rccm.201401-0065st
The paper
Klings, E. S., Machado, R. F., Barst, R. J., Morris, C. R., Mubarak, K. K., Gordeuk, V. R., Kato, G. J., Ataga, K. I., Gibbs, J. S., Castro, O., Rosenzweig, E. B., Sood, N., Hsu, L., Wilson, K. C., Telen, M. J., DeCastro, L. M., Krishnamurti, L., Steinberg, M. H., Badesch, D. B., & Gladwin, M. T. (2014). An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201401-0065st

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.